期刊文献+

欧洲治疗阿尔茨海默病药物指导原则(译文) 被引量:2

European Guidance on Clinical Investgation of Medical Products for the Treatment of Alzheimer's Disease
暂未订购
导出
摘要 本文介绍了阿尔茨海默病痴呆的定义及诊断标准。确定了AD疗效评价的主要目标是:症状改善;减慢或阻止症状的发展;初级预防。目前在后两个方面还缺乏经验,所以对症状改善的评价应为重点,包括认知功能测试、日常生活能力量表及临床总体评价。建议用多种适当的测试工具对不同方面进行评价。为确定短期疗效,设有对照的Ⅲ期临床试验应持续6个月,停药后应随访2个月。 These notes introduce the definition, criteria of diagnosis and selection for Alzheimer's Disease. The main goals of AD treatment are established : symptomatic improvement; slowing or arrest; primary prevention. This guideline concentrates on assessment of symptomatic improvement in so far as, for the time being, experience is lacking in either slowing or arresting of symptom progression or in the primary prevention of disease. Improvement of symptoms should be assessed in three areas : 1. cognition; 2. activities of daily living; 3. overall clinical response. It suggests making assessment in various areas by many kinds of instrument. Phase III controlled clinical trials aimed at demonstrating short term improvement should last 6 months. After the end of the treatment administration, the state of the patient should be observed for at least 2 months.
作者 卓宏 赵德恒
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2000年第1期69-72,共4页 The Chinese Journal of Clinical Pharmacology
关键词 欧洲 阿尔茨海默病 药物治疗 指导原则 诊断标准 AD 疗效评价 Alzheimer's disease drug guidance
  • 相关文献

同被引文献5

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部